I read the transcript of the Tandem Quarterly call yesterday. Here were a few highlights. Note: I just downloaded the t:connect app which doesn’t seem too incremental quite yet.
"In the next 12 months, we are focused on preparing to bring three new products and features to market in the U.S. including the launch of our t:connect mobile app, which is underway now, the future edition of the mobile bolus delivery feature through an app and the clearance of the t:sport insulin delivery system.
As a reminder, our t:connect mobile app is the center of our digital health strategy moving forward, which is why we took a more metered approach to its launch over the past few weeks. Even without broad promotion, approximately 15,000 people have downloaded the app since its release for both Android and iOS devices. Most importantly, the feedback on the user experience of the app has been excellent and we are confident in its ability to serve as a foundation for future offerings."
“T:sport is meaningful to our business as it expands the family of insulin pump offerings and offers customers a choice depending on whether they prefer to program their therapy management using a touchscreen on the pump, or they prefer a pump that’s about half the size and fully controlled through a mobile app. Both platforms will offer the latest automated insulin delivery algorithm. I’m happy to share that human factors testing for t:sport is now underway.”
“Also in support of this strategy, we continue to advance our internal development efforts on features and enhancements of our Control-IQ technology. We aren’t providing a schedule yet for competitive reasons, but broadly they are centered around algorithm enhancements that are intended to further improve clinical outcomes, new features with greater personalization and refinement of the overall systems usability. We are planning the first of our Control-IQ updates in the second half of 2021.”